Table 1.
No. | Sex | Original tumor | Metastatic site | Prescription dose (Gy) | % Decrease in gadolinium | % Decrease in T2 | KPS change |
---|---|---|---|---|---|---|---|
1 | F | Lung adenocarcinoma | Left temporal and parietal | 22 | 21 | 86 | 50 |
2 | F | Lung adenocarcinoma | Left occipital | 20 | 18 | 83 | 50 |
3 | F | Lung adenocarcinoma | Right parietal | 18 | 27 | 45 | 40 |
4 | M | Lung adenocarcinoma | Left frontal | 15 | 82 | 59 | 50 |
5 | F | Lung adenocarcinoma | Right frontal and parietal | 20 | 34 | 52 | 20 |
6 | F | Lung adenocarcinoma | Left occipital | 20 | 55 | 72 | 10 |
7 | M | Lung adenocarcinoma | Right frontal | 18 | 10 | 64 | 10 |
8 | M | Neuroendocrine lung cancer | Right parietal | 24 | 34 | 61 | 40 |
9 | M | Small cell lung cancer | Left posteior horn of lateral ventricle | 24 | 82 | 80 | 40 |
10 | M | Small cell lung cancer | Right parietal and occipital | 25 | 49 | 79 | 40 |
11 | F | Breast cancer | Left frontal | 24 | 38 | 81 | 40 |
12 | M | Renal clear cell carcinoma | Left frontal | 22 | 31 | 69 | 40 |
13 | M | Maxillary sinus carcinoma | Right temporal | 15 | 42 | 79 | 50 |
14 | M | Esophageal cancer | Right occiptal | 24 | 56 | 83 | 10 |
15 | M | Lung adenocarcinoma | Right parietal | 20 | 23 | 82 | 40 |
16 | M | Lung adenocarcinoma | Left parietal | 18 | 70 | 90 | 30 |
17 | F | Lung adenocarcinoma | Right frontal | 22 | 73 | 85 | 40 |
18 | M | Lung adenocarcinoma | Right posteior horn of lateral ventricle | 15 | 33 | 85 | 20 |
19 | F | Lung adenocarcinoma | Left frontal | 22 | 67 | 66 | 20 |
20 | F | Lung adenocarcinoma | Right posteior horn of lateral ventricle | 22 | 81 | 85 | 20 |
21 | F | Breast cancer | Right frontal | 15 | 30 | 78 | 30 |
22 | F | Ovarian cancer | Left temporal | 20 | 28 | 68 | 20 |